NATIONAL COMMUNITY PHARMACISTS ASSOCIATION for NATIONAL COMMUNITY PHARMACISTS ASSOCIATION
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Alcohol and Drug Abuse ALC
Controlled Substances Prescribing & Dispensing; Comments to DOJ & DEA on "Ensuring Lawful Governance and Implementing the Presidents 'Department of Government Efficiency' Deregulatory Initiative"; Comments to DEA on "Special Registrations for Telemedicine and Limited State Telemedicine Registrations [Docket No. DEA-407]"
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Medicare/Medicaid MMM
S.891, the Bipartisan Health Care Act; S.882, the Patients Before Middlemen Act; S.927, the Protecting Pharmacies in Medicaid Act; H.R.3164, the Ensuring Community Access to Pharmacist Services Act; H.R.2428, the Ensuring Access to Lower-Cost Medicines for Seniors Act; Comments to CMS on the implementation of Medicare Part D Medicare Drug Price Negotiation implementation under the Inflation Reduction Act (IRA; P.L. 117-169); Long-Term Care Pharmacy at Home Services in Medicare; Comments to CMS for its "Dispensing Entity-CMS Agreement and Dispensing Entity-MTF Data Module Contractor Agreement" (IRA; P.L.117-169)' H.R.1, the One Big Beautiful Bill Act Comments to CMS on "Re: Draft Guidance for IPAY 2028 and Manufacturer Effectuation of the MFP for 2026, 2027, and 2028 for the Medicare Drug Price Negotiation Program"; Comments to CMS on "Re: Medicare Transaction Facilitator DRAFT Standard Companion Guide Health Care Claim Payment/Advice (835)" Comments to CMS on "Re: Agency Information Collection Activities: Proposed Collection; Comment Request [Docket No. CMS-10912] - CMS-10912 Medicare Transaction Facilitator for 2026 and 2027 under Sections 11001 and 11002 of the Inflation Reduction Act (IRA) - Drug Price Negotiation Program MTF DM Dispensing Entity and Third-Party Support Enrollment Form"; H.Con.Res.14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Pharmacy PHA
H.R. 2214, the Delinking Revenue from Unfair Gouging Act; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R. 1, the One Big Beautiful Bill; Comments to FDA on "Re: Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs From Bulk Drug Substances [Docket No. FDA-2025-N-0082]"; LHHS Report Language Request to Improve the Care and Treatment of Long-Term Care Residents with Neuropsychiatric Symptoms; Comments to OMB on "Re: Request for Information: Deregulation"; Comments to HHS/DOGE on government efficiency, fraud, waste and PBMs; Comments on "Executive Order 14297 of May 12, 2025 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients"; Comments to CDC on "RE: June 25-26 Advisory Committee on Immunization Practices Meeting";
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Taxation/Internal Revenue Code TAX
S.587/1301, The Death Tax Repeal Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Labor Issues/Antitrust/Workplace LBR
S.526, the Pharmacy Benefit Manager Transparency Act of 2025; S.527, the Prescription Pricing for the People Act of 2025;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Defense DEF
TRICARE Pharmacy Network Oversight & Changes; National Defense Authorization Act for Fiscal Year 2026;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Budget/Appropriations BUD
H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025; H.Con.Res 14/S. Con. Res. 7, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034; H.R.1, the One Big Beautiful Bill Act;
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| DAVID JEREMY WEISSMAN | — |
Telecommunications TEC
Comments to HHS on "HIPAA Security Rule To Strengthen the Cybersecurity of Electronic Protected Health Information [HHS-OCR-0945-AA22]";
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| KAITLIN KRELL | — |
| STEVEN W POSTAL | — |
| DAVID JEREMY WEISSMAN | — |
Trade (domestic/foreign) TRD
Comments to CBP on "June 14, 2024, Internal Advice Letter H283420"; Comments to on "Re: Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients [XRIN 0694- XC120]";
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| STEVEN W POSTAL | — |
Small Business SMB
Comments to the White House on the Corporate Transparency Act implementations (NDAA; P.L.116-283);
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANNE CASSITY | — |
| RONNA HAUSER | — |
| STEVEN W POSTAL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.